About: http://data.cimple.eu/news-article/2359c6e34c2d007fc176c75145cb4660d690e6c94a83642ac36bd69d

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/2359c6e34c2d007fc176c75145cb4660d690e6c94a83642ac36bd69d Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	A repurposed arthritis drug has shown positive results in a clinical trial of patients hospitalized with Covid-19, according to a paper published Wednesday in the New England Journal of Medicine. Tofacitinib, taken orally and sold under the brand name Xeljanz among others, was tested in a trial of 289 patients hospitalized with severe Covid across 15 locations in Brazil. Half received the drug -- a 10 mg pill twice a day -- and standard care like glucocorticoids that tamp down an overactive immune response, while the other half received a placebo and standard care. After 28 days, 18.1 percent of the group receiving the tofacitinib progressed to respiratory failure or death, compared to 29 percent in the placebo group. This represented a statistically significant relative risk reduction of 63 percent. Respiratory failure refers to a patient requiring noninvasive ventilation through an oxygen mask, or being intubated and placed on a mechanical ventilator. Deaths after 28 days occurred in 2.8 percent of patients in the tofacitinib group and in 5.5 percent of those in the placebo group. Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group. "We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with COVID-19 pneumonia," said Otavio Berwanger of Hospital Israelita Albert Einstein, which coordinated the trial in collaboration with Pfizer. "These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population." Tofacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors. It is approved in the United States to treat conditions including rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. ia/ft
schema:headline	Arthritis drug shows promise against severe Covid: study
schema:mentions	Relative risk reduction Mechanical ventilation Oxygen mask Clinical trial Arthritis New England Placebo Pneumonia Ia (cuneiform) Immune system Janus kinase Pfizer Coronavirus disease Brazil United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Tofacitinib Albert Einstein Israelite Hospital Glucocorticoid Non-invasive ventilation Psoriatic arthritis Intubation Ulcerative colitis Rheumatoid arthritis Tamp Randomized controlled trial Respiratory failure Progressed (EP)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-06-16 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	77 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software